NasdaqGS:ARQTBiotechs
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Reaffirming 2026 Guidance And Advancing ZORYVE sNDA
In early May 2026, Arcutis Biotherapeutics reported first-quarter 2026 results showing revenue of US$105.4 million versus US$65.85 million a year earlier, with net loss narrowing to US$11.3 million and basic loss per share improving to US$0.09, while reaffirming full-year 2026 net product revenue guidance of US$480 million to US$495 million.
Alongside these results, Arcutis advanced ZORYVE’s label expansion by filing an FDA supplemental New Drug Application to treat mild to moderate atopic...